Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) EBIT: 2023-2025

Historic EBIT for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -$10.0 million.

  • Mereo BioPharma Group's EBIT fell 6.85% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$47.0 million, marking a year-over-year decrease of 19.83%. This contributed to the annual value of -$47.4 million for FY2024, which is 66.68% down from last year.
  • Mereo BioPharma Group's EBIT amounted to -$10.0 million in Q3 2025, which was up 4.61% from -$10.5 million recorded in Q2 2025.
  • Mereo BioPharma Group's 5-year EBIT high stood at -$811,000 for Q2 2023, and its period low was -$15.3 million during Q4 2024.
  • Over the past 3 years, Mereo BioPharma Group's median EBIT value was -$10.0 million (recorded in 2025), while the average stood at -$9.8 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's EBIT tumbled by 1,480.02% in 2024, and later climbed by 18.07% in 2025.
  • Mereo BioPharma Group's EBIT (Quarterly) stood at -$7.1 million in 2023, then tumbled by 114.30% to -$15.3 million in 2024, then dropped by 6.85% to -$10.0 million in 2025.
  • Its last three reported values are -$10.0 million in Q3 2025, -$10.5 million for Q2 2025, and -$11.2 million during Q1 2025.